MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly Income towards Parent Company came in at -$80.9 million in Q4 2025, down 269.81% year-on-year from $47.6 million in Q4 2024, and down 170.15% quarter-over-quarter from -$29.9 million in Q3 2025.
MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed Income towards Parent Company across 2 years of filings, most recently posting -$80.9 million for Q4 2025.
- Income towards Parent Company for Q4 2025 came in at -$80.9 million, down 269.81% year-over-year; the trailing twelve-month figure through Dec 2025 was -$152.5 million (changed N/A YoY), and the FY2025 annual result was -$163.6 million, down 108.52% from the prior year.
- Income towards Parent Company came in at -$80.9 million for Q4 2025 at MapLight Therapeutics, down from -$29.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$19.8 million in Q3 2024 to a low of -$80.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -80.91 Mn |
| Sep 30, 2025 | -29.95 Mn |
| Dec 31, 2024 | -21.88 Mn |
| Sep 30, 2024 | -19.81 Mn |